Yarrow Bioscience (YARW) Other Working Capital Changes (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Other Working Capital Changes came in at -$37000.0 in Q2 2025, down 5.71% YoY from -$39242.4 in Q2 2024, and little changed on a QoQ basis from -$37000.0 in Q1 2025.
Yarrow Bioscience (YARW) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Other Working Capital Changes data on file, last reported at -$37000.0 in Q2 2025.
- Quarterly Other Working Capital Changes fell 5.71% year-over-year to -$37000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$97000.0 (up 17.09% YoY) and the FY2025 annual result came in at -$99000.0, up 13.16% from the prior year.
- Other Working Capital Changes held at -$37000.0 in Q2 2025, from -$37000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $2.8 million in Q2 2024 to a low of -$9.5 million in Q4 2022.
- A 5-year average of -$809769.2 and a median of -$492000.0 in 2023 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2021 — Other Working Capital Changes plunged 120700.0% — and 2025, when it declined 5.71%.
- Tracing YARW's Other Working Capital Changes over 5 years: stood at -$1.2 million in 2021, then jumped by 97.43% to -$31000.0 in 2022, then jumped by 790.32% to $214000.0 in 2023, then sank by 110.75% to -$23000.0 in 2024, then plunged by 60.87% to -$37000.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$37000.0 (Q2 2025), -$37000.0 (Q1 2025), and -$23000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -260,000.00 |
| Jun 30, 2026 | -260,000.00 |
| Jun 30, 2026 | -260,000.00 |
| Mar 31, 2026 | -202,000.00 |
| Mar 31, 2026 | -202,000.00 |
| Mar 31, 2026 | -202,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 768,000.00 |
| Mar 31, 2025 | 768,000.00 |
| Mar 31, 2025 | 768,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Sep 30, 2024 | -2.54 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |